PDF DatasheetHuman Anti-CD22 / BL-CAM Antibody Product Attributes
CD22 / BL-CAM Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD22 / BL-CAM antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the white pulp in spleen and germinal center cells in the tonsil. More moderate antibody staining intensity was present in cells in the white pulp in spleen and germinal center cells in the tonsil. Low, but measureable presence of CD22 / BL-CAM could be seen innon-germinal center cells in the lymph node. We were unable to detect CD22 / BL-CAM in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD22 / BL-CAM expression as measured by anti-CD22 / BL-CAM antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | + | – | – | – | – | – | – | – | – | – | – |
| CD22 Variability | + | + | + | + | + | + | + | + | + | ++ | + | + | + | + | + | + | + | + | + | + |
| CD22 / BL-CAM General Information | |
|---|---|
| Alternate Names | |
| CD22, Cluster of Differentiation 22 | |
| Molecular Weight | |
| 130-140kDa | |
| Chromosomal Location | |
| 19q13.1 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CD22 |
| Entrez Gene ID | 933 |
| Ensemble Gene ID | ENSG00000012124 |
| RefSeq Protein Accession(s) | NP_001172028, NP_001172029, NP_001265346, NP_001762, NP_001172030 |
| RefSeq mRNA Accession(s) | NM_001185101, NM_001278417, NM_001185100, NM_001771, NM_024916, NM_001185099 |
| RefSeq Genomic Accession(s) | NC_018930, NC_000019, |
| UniProt ID(s) | Q0EAF5, P20273 |
| UniGene ID(s) | Q0EAF5, P20273 |
| HGNC ID(s) | 1643 |
| Cosmic ID(s) | CD22 |
| KEGG Gene ID(s) | hsa:933 |
| PharmGKB ID(s) | PA26201 |
| General Description of CD22 / BL-CAM. | |
| Recognizes a protein of 130-140kDa, identified as CD22 (also known as BL-CAM). CD22 expression is restricted to normal and neoplastic B cells and is absent from other haemopoietic cell types. In B-cell ontogeny, CD22 is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. It is not expressed by plasma cells, CD22 is found highly expressed in follicular mantle and marginal zone B-cells, and while germinal center B-cells are relatively weak. CD22 is a member of the immunoglobulin superfamily and serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. It also associates with tyrosine kinases and play a role in signal transduction and B-cell activation. | |
There are no reviews yet.